Cardiology

Luke Laffin, MD, discusses his secondary analysis of the phase 2 KARDINAL trial, which demonstrated substantial improvements in uncontrolled hypertension.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

Robert Giugliano, MD, breaks down his prespecified subanalysis of the VESALIUS-CV trial, evaluating evolocumab’s effect on cardiovascular mortality.

Sadiya Khan, MD, MSc, discusses the session she chaired at ESC 2026, which saw clinicians discuss the equitability of artificial intelligence in medicine.

Oyvind Lie, MD, PhD, MSc, discusses the results from the ACASA-TAVI trial, which sought to evaluate the efficacy of anticoagulant monotherapy in this population.

Jose Nicolau, MD, PhD, discusses the results of his subanalysis of the VESALIUS-CV trial, examining secondary rather than first MACE.

ESC and ERA issue the first dedicated guideline on managing cardiovascular disease alongside chronic kidney disease, via a “STAMP on CKD” framework.

Catch up on any stroke-related news you may have missed during 4 action-packed days of presentations and trial readouts at ESC 2026.

Ankeet Bhatt, MD, MBA, discusses the effectiveness of text, email, and secure portal message reminders for encouraging patients to keep up with their treatment.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Sharmila Dorbala, MD, MPH, discusses how this treatment and imaging strategy may lead to a diagnostic overhaul for patients with amyloidosis.

Abbott's dual-energy PFA/RF ablation catheter met its primary effectiveness and safety endpoints in the 12-month FlexPulse IDE study behind its FDA nod.

Rahul Aggarwal, MD, MBA, shares the results of his retrospective cohort study investigating the residual risk of heart failure after patients with prior MI.

Pooled data from 3 trials show H-ISDN cuts all-cause and cardiovascular death in HFrEF, though heterogeneity limits clinical impact.

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

Charalambos Antoniades, MD, PhD, discusses the recent trial investigating an AI-powered stroke and atrial fibrillation predictor.

Deepak Bhatt, MD, MPH, MBA, discusses the next steps for pacibekitug in cardiovascular disease following its success in the phase 2 trial.

Novartis announced pelacarsen did not meet its primary endpoint in the phase 3 Lp(a)HORIZON cardiovascular outcomes trial despite Lp(a) lowering.

A post hoc ALPACA analysis presented at ESC Congress 2026 shows lepodisiran cut Lp(a)-bound oxidized phospholipids by up to 94% at the 400-mg dose.

Deepak Bhatt, MD, MPH, MBA, discusses the efficacy of this investigational IL-6 antibody among patients at high inflammatory risk.

PAH specialists discuss sotatercept, risk-based escalation, and access barriers shaping pulmonary arterial hypertension care.

The ASPIRED trial found immediate ECG monitoring in the ED did not reduce recurrent syncope but doubled arrhythmia detection and cut mortality.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

H-ISDN missed its primary endpoint in H-HeFT, but a pooled meta-analysis found significant reductions in all-cause and cardiovascular death in HFrEF.